Schroder UK Public Private Trust, the rebranded fund previously led by Neil Woodford, has sold its shareholding in Carrick Therapeutics at a discount.

Schroder UK Public Private Trust, the investment vehicle operated by asset manager Schroder, has dumped its shareholding in Carrick Therapeutics, an Ireland-based biopharmaceutical spinout of University of Cambridge, according to the Irish Times.
The trust sold its stake, valued at £18.2m ($23.4m) in September 2020, to venture capital firm Rosetta Capital as part of a deal that included six other holdings. Rosetta paid $72.4m for the package deal, representing a 22% aggregate discount.
Founded in 2015, Carrick Therapeutics…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.